Xaracoll is owned by Innocoll Pharms.
Xaracoll contains Bupivacaine Hydrochloride.
Xaracoll has a total of 1 drug patent out of which 0 drug patents have expired.
Xaracoll was authorised for market use on 28 August, 2020.
Xaracoll is available in implant;implantation dosage forms.
Xaracoll can be used as a method for inducing a post-surgical analgesia sparing effect by implanting at the surgical site a collagen sponge containing bupivacaine hcl which provides local anesthesia for up to 24 hours following implantation.
The generics of Xaracoll are possible to be released after 20 May, 2029.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE47826 | INNOCOLL PHARMS | Drug delivery device for providing local analgesia, local anesthesia or nerve blockage |
May, 2029
(5 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Aug 28, 2023 |
Drugs and Companies using BUPIVACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 August, 2020
Treatment: A method for inducing a post-surgical analgesia sparing effect by implanting at the surgical site a collagen sponge containing bupivacaine hcl which provides local anesthesia for up to 24 hours follow...
Dosage: IMPLANT;IMPLANTATION
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic